1. Home
  2. ARRY vs AUPH Comparison

ARRY vs AUPH Comparison

Compare ARRY & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Array Technologies Inc.

ARRY

Array Technologies Inc.

HOLD

Current Price

$6.69

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$13.98

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARRY
AUPH
Founded
1989
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.6B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
ARRY
AUPH
Price
$6.69
$13.98
Analyst Decision
Buy
Buy
Analyst Count
19
4
Target Price
$10.24
$17.25
AVG Volume (30 Days)
6.3M
937.4K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
62.56
5075.00
EPS
N/A
2.07
Revenue
$1,284,141,000.00
$283,055,000.00
Revenue This Year
$15.64
$16.53
Revenue Next Year
$7.95
$16.24
P/E Ratio
N/A
$6.78
Revenue Growth
40.22
20.38
52 Week Low
$3.76
$6.83
52 Week High
$12.23
$16.54

Technical Indicators

Market Signals
Indicator
ARRY
AUPH
Relative Strength Index (RSI) 32.52 43.02
Support Level $6.51 $13.52
Resistance Level $8.10 $15.23
Average True Range (ATR) 0.42 0.44
MACD 0.02 -0.03
Stochastic Oscillator 0.43 8.06

Price Performance

Historical Comparison
ARRY
AUPH

About ARRY Array Technologies Inc.

Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: